Medicines Discovery Catapult celebrates five years of achievement

This will include a selection from the more than 230 projects with over 170 partners across the UK, which has assisted companies in raising in excess of £600 million in private funding and driving the successful adoption of new imaging and biomarker-based technologies.

MDC will also highlight five of its most effective collaborations on social media. These include Alchemab, supporting novel disease-modifying antibody therapy for Huntington's disease; anticoagulant treatment Lunac; developing the N4 Pharma drug delivery system; data-driven drug discovery; and the Psychiatry Consortium for the therapeutic needs of people with mental health conditions.

MDC also coordinated the largest diagnostics laboratory testing project in UK history during the pandemic when the UK Lighthouse Lab Network performed 98% of the UK Government’s Covid-19 PCR testing.

MDC Chief Strategic Impact Officer at Medicines Discovery Catapult Dr Nicola Heron commented:

"MDC's breadth of impact throughout our first five years is far-reaching and a testament to the skill and determination of our strong team of specialists.

They have worked tirelessly to identify and address the barriers faced by our drug discovery innovators … created world-class consortia in areas of critical patient need, provided international thought leadership and stepped up during a time of national crisis.”